Performance of RCUS Arcus Biosciences | -7.5% in 12m
Compare RCUS with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Arcus Biosciences with its related Sector/Index XBI
Performance Duell RCUS vs XBI
| TimeFrame | RCUS | XBI |
|---|---|---|
| 1 Day | -3.21% | -1.52% |
| 1 Week | -1.80% | 1.45% |
| 1 Month | 15.8% | 10.08% |
| 3 Months | 1.81% | -1.30% |
| 6 Months | 21.1% | 24.09% |
| 12 Months | -7.50% | 6.83% |
| YTD | -14.1% | 1.05% |
| Rel. Perf. 1m | 0.41 | |
| Rel. Perf. 3m | -1.44 | |
| Rel. Perf. 6m | -0.89 | |
| Rel. Perf. 12m | -1.27 |
Is Arcus Biosciences a good stock to buy?
No, based on ValueRay Fundamental Analyses, Arcus Biosciences (NYSE:RCUS) is currently (May 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -62.15 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RCUS as of May 2024 is 14.88. This means that RCUS is currently overvalued and has a potential downside of -11.95% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RCUS as of May 2024 is 14.88. This means that RCUS is currently overvalued and has a potential downside of -11.95% (Sold with Premium).
Is RCUS a buy, sell or hold?
- Strong Buy: 7
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
Values above 0%: RCUS is performing better - Values below 0%: RCUS is underperforming
Compare RCUS with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -3.44% | 8.90% | 3.67% | -35.81% |
| US NASDAQ 100 | QQQ | -3.76% | 6.88% | 5.00% | -42.65% |
| US Dow Jones Industrial 30 | DIA | -3.19% | 10.37% | 6.28% | -29.41% |
| German DAX 40 | DBXD | -1.56% | 10.68% | 3.90% | -21.88% |
| UK FTSE 100 | ISFU | -3.34% | 6.28% | 4.82% | -22.15% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -2.95% | 11.10% | 18.94% | -0.22% |
| Hongkong Hang Seng | HSI | -3.95% | -7.03% | 17.37% | -2.09% |
| Japan Nikkei 225 | EXX7 | -2.86% | 14.95% | 9.28% | -18.23% |
| India NIFTY 50 | INDA | -4.22% | 12.63% | 3.48% | -37.32% |
| Brasil Bovespa | EWZ | -1.71% | 12.54% | 24.82% | -20.21% |
RCUS Arcus Biosciences vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -2.99% | 11.88% | 3.88% | -43.28% |
| Consumer Discretionary | XLY | -2.27% | 10.56% | 14.27% | -26.33% |
| Consumer Staples | XLP | -2.85% | 10.77% | 6.74% | -13.53% |
| Energy | XLE | -3.27% | 15.84% | 7.10% | -30.86% |
| Financial | XLF | -3.79% | 10.60% | -0.87% | -40.16% |
| Health Care | XLV | -3.79% | 10.53% | 6.75% | -20.75% |
| Industrial | XLI | -1.94% | 11.80% | 1.73% | -35.21% |
| Materials | XLB | -2.20% | 12.24% | 5.24% | -27.10% |
| Real Estate | XLRE | -4.04% | 7.80% | 12.26% | -18.36% |
| Technology | XLK | -4.37% | 5.81% | 6.40% | -43.10% |
| Utilities | XLU | -3.30% | 5.27% | 2.50% | -20.69% |
| Aerospace & Defense | XAR | -2.87% | 7.47% | 6.81% | -31.93% |
| Biotech | XBI | -3.25% | 5.75% | -3.03% | -14.33% |
| Homebuilder | XHB | -2.38% | 8.83% | -9.20% | -58.35% |
| Retail | XRT | -1.32% | 9.14% | 0.96% | -37.00% |
Does Arcus Biosciences outperform its market, is RCUS a Sector Leader?
No, over the last 12 months Arcus Biosciences (RCUS) made -7.50%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.83%.
Over the last 3 months RCUS made 1.81%, while XBI made -1.30%.
No, over the last 12 months Arcus Biosciences (RCUS) made -7.50%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.83%.
Over the last 3 months RCUS made 1.81%, while XBI made -1.30%.
| Period | RCUS | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 15.83% | 10.08% | 6.93% |
| 3 Months | 1.81% | -1.30% | 6.91% |
| 12 Months | -7.50% | 6.83% | 28.31% |